Compare AbbVie Inc (ABBV) vs Global X Cloud Computing ETF (CLOU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbbVie Inc vs Global X Cloud Computing ETF — how do they compare? AbbVie Inc trades at $249.5 (market cap $438.19B), while Global X Cloud Computing ETF trades at $27.72. The key difference: AbbVie Inc pays a 2.79% dividend while Global X Cloud Computing ETF pays none, and Global X Cloud Computing ETF is trading nearer its 52-week high, AbbVie Inc nearer its low. Which is the better fit depends on your goals.
| ABBV | CLOU | |
|---|---|---|
Market Cap | $438.19B | — |
Sector | Health | Sector/Thematic |
52-Week High | $263.58 | $28.09 |
52-Week Low | $197.38 | $17.60 |
Enterprise Value | $502.45B | — |
Dividend Yield | 2.79% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABBV trades at $247.91, up 0.76% today, with a bullish technical signal supported by moving averages and oversold RSI levels. The company reported Q2 2026 EPS of $3.65, beating expectations, and maintains strong profitability with a 71.48% gross margin. Recent news highlights positive Phase 2 data for ELAHERE in ovarian cancer, reinforcing growth prospects beyond Humira's patent expiry.
Outlook is positive with analyst consensus target of $278.69, though high P/E of 70.05 and debt levels pose valuation and financial risks. Revenue growth driven by Skyrizi and Rinvoq offsets competitive pressures, but patent cliffs in the 2030s require monitoring. The stock offers dividend appeal with a $1.73 payout scheduled for August 2026.
CLOU, the Global X Cloud Computing ETF, trades at $27.28, up 3.88% in the past 24 hours. Technical indicators show a bullish trend with strong moving average support, though RSI levels suggest potential overbought conditions. Recent news highlights long-term growth prospects driven by cloud computing expansion beyond AI, with top holdings like Snowflake and Datadog showing resilience.
The outlook for CLOU remains positive due to sector tailwinds and diversified cloud exposure, but risks include market volatility and competition from European tech initiatives. Investors should weigh growth potential against valuation concerns in the tech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Global X Cloud Computing ETF
CLOU is a thematic ETF that invests in companies leading the cloud revolution. It targets providers of SaaS, PaaS, and IaaS, including major firms like Salesforce, Akamai, and Shopify that drive modern digital infrastructure.
Read more on CLOU →
